What is Avalo Therapeutics Inc's earnings per share (EPS)?

Avalo Therapeutics Inc (AVTX) reported diluted earnings per share of $-5.84 for fiscal year 2025. This represents a 72.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Avalo Therapeutics Inc Financials

AVTX

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows Avalo Therapeutics Inc (AVTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 48/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Avalo Therapeutics Inc's revenue declined 100% year-over-year, from $441K to $0. This contraction results in a growth score of 0/100.

Leverage

Avalo Therapeutics Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 8.14, Avalo Therapeutics Inc holds $8.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Avalo Therapeutics Inc generates a -94.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -26.4% the prior year.

Piotroski F-Score Weak

1/9

Avalo Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, Avalo Therapeutics Inc generates $0.66 in operating cash flow (-$51.5M OCF vs -$78.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Avalo Therapeutics Inc generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$72.6M

YoY-6.2%

Avalo Therapeutics Inc's EBITDA was -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.2% from the prior year.

Net Income

-$78.3M

YoY-122.8%

Avalo Therapeutics Inc reported -$78.3M in net income in fiscal year 2025. This represents a decrease of 122.8% from the prior year.

EPS (Diluted)

$-5.84

YoY+72.1%

Avalo Therapeutics Inc earned $-5.84 per diluted share (EPS) in fiscal year 2025. This represents an increase of 72.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$59.0M

Avalo Therapeutics Inc generated -$59.0M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$15.9M

YoY-88.2%

5Y CAGR-3.5%

10Y CAGR-2.8%

Avalo Therapeutics Inc held $15.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

23M

YoY+117.6%

Avalo Therapeutics Inc had 23M shares outstanding in fiscal year 2025. This represents an increase of 117.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-94.2%

YoY-67.8pp

5Y CAGR+164.3pp

10Y CAGR-14.1pp

Avalo Therapeutics Inc's ROE was -94.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 67.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$50.1M

YoY+105.0%

5Y CAGR+9.2%

10Y CAGR+22.5%

Avalo Therapeutics Inc invested $50.1M in research and development in fiscal year 2025. This represents an increase of 105.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$7.5M

5Y CAGR+160.1%

10Y CAGR+80.9%

Avalo Therapeutics Inc invested $7.5M in capex in fiscal year 2025, funding long-term assets and infrastructure.

AVTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$441K-77.1%	$1.9M-89.3%	$18.1M+234.4%	$5.4M-19.4%	$6.7M
Cost of Revenue	N/A	N/A	$1.3M-62.6%	$3.4M+130.3%	$1.5M+397.0%	$300K
Gross Profit	N/A	N/A	$640K-95.6%	$14.6M+274.1%	$3.9M-38.9%	$6.4M
R&D Expenses	$50.1M+105.0%	$24.4M+77.3%	$13.8M-56.0%	$31.3M-47.7%	$59.8M+85.9%	$32.2M
SG&A Expenses	$22.9M+32.8%	$17.2M+67.4%	$10.3M-50.3%	$20.7M-16.0%	$24.7M+41.6%	$17.4M
Operating Income	-$72.9M-6.4%	-$68.5M-150.5%	-$27.4M+26.9%	-$37.4M+54.4%	-$82.1M-12.8%	-$72.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$165K+44.7%	$114K+714.3%	$14K-50.0%	$28K+114.3%	-$196K+93.0%	-$2.8M
Net Income	-$78.3M-122.8%	-$35.1M-11.4%	-$31.5M+24.3%	-$41.7M+50.6%	-$84.4M-32.9%	-$63.5M
EPS (Diluted)	$-5.84+72.1%	$-20.91+81.6%	$-113.58+89.3%	$-1063.00	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	N/A	N/A	N/A	$249K	$0	$0-100.0%	$570K
Cost of Revenue	N/A	$0	N/A	N/A	-$714K-308.2%	$343K+528.8%	-$80K+64.0%	-$222K
Gross Profit	N/A	N/A	N/A	N/A	N/A	-$343K	N/A	$792K
R&D Expenses	$13.6M-3.2%	$14.1M+54.3%	$9.1M	N/A	$9.5M+107.3%	$4.6M+117.4%	$2.1M+13.2%	$1.9M
SG&A Expenses	$5.6M+6.4%	$5.2M-5.5%	$5.5M	N/A	$4.3M-5.3%	$4.5M+41.8%	$3.2M+19.4%	$2.7M
Operating Income	-$19.2M+0.6%	-$19.3M-31.7%	-$14.7M	N/A	-$12.9M-34.3%	-$9.6M+70.8%	-$32.8M-327.8%	-$7.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$11K-31.3%	$16K+100.0%	$8K	N/A	-$14K-300.0%	$7K0.0%	$7K+177.8%	-$9K
Net Income	-$30.6M-47.5%	-$20.8M-57.9%	-$13.1M	N/A	$23.0M-76.6%	$98.5M+181.2%	-$121.3M-1384.9%	-$8.2M
EPS (Diluted)	$-2.19-14.1%	$-1.92-53.6%	$-1.25	N/A	$-2.83	$-14.07+90.0%	$-141.14	N/A

AVTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$116.5M-22.7%	$150.7M+618.0%	$21.0M-37.1%	$33.4M-58.4%	$80.2M+83.3%	$43.8M
Current Assets	$105.3M-24.2%	$138.9M+1554.4%	$8.4M-48.9%	$16.4M-73.5%	$61.8M+137.8%	$26.0M
Cash & Equivalents	$15.9M-88.2%	$134.5M+1714.5%	$7.4M-43.7%	$13.2M-75.9%	$54.6M+188.5%	$18.9M
Inventory	N/A	N/A	$0-100.0%	$20K-47.4%	$38K+1166.7%	$3K
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$1.1M-51.3%	$2.2M
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M-27.1%	$14.4M0.0%	$14.4M0.0%	$14.4M
Total Liabilities	$33.4M+88.8%	$17.7M+29.3%	$13.7M-69.1%	$44.3M-22.5%	$57.1M+197.7%	$19.2M
Current Liabilities	$12.9M+85.9%	$7.0M+50.7%	$4.6M-79.1%	$22.1M+11.2%	$19.9M+30.6%	$15.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$83.0M-37.6%	$133.0M+1721.4%	$7.3M+166.9%	-$10.9M-147.3%	$23.1M-6.0%	$24.6M
Retained Earnings	-$448.5M-21.1%	-$370.3M-10.5%	-$335.1M-10.3%	-$303.8M-15.9%	-$262.2M-47.5%	-$177.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$125.1M-1.2%	$126.6M-8.6%	$138.5M-8.1%	$150.7M+53.1%	$98.5M-9.1%	$108.3M-12.5%	$123.7M+489.4%	$21.0M
Current Assets	$113.8M-1.2%	$115.2M-9.3%	$126.9M-8.6%	$138.9M+61.2%	$86.1M-10.2%	$95.9M-13.8%	$111.2M+1224.8%	$8.4M
Cash & Equivalents	$27.0M-36.2%	$42.3M-66.2%	$125.0M-7.1%	$134.5M+64.4%	$81.9M-12.4%	$93.4M-15.2%	$110.2M+1385.9%	$7.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M
Total Liabilities	$33.6M+52.5%	$22.0M+38.4%	$15.9M-10.1%	$17.7M-76.6%	$75.7M-31.4%	$110.5M-50.9%	$224.8M+1542.3%	$13.7M
Current Liabilities	$8.0M-13.9%	$9.3M+64.9%	$5.6M-19.3%	$7.0M-88.5%	$60.7M-37.1%	$96.4M-55.3%	$215.7M+4570.9%	$4.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$91.5M-12.5%	$104.6M-14.7%	$122.6M-7.8%	$133.0M+531.2%	$21.1M+254.9%	-$13.6M+87.9%	-$112.5M-1640.8%	$7.3M
Retained Earnings	-$434.8M-7.6%	-$404.2M-5.4%	-$383.4M-3.6%	-$370.3M-10.6%	-$334.9M+6.4%	-$358.0M+21.6%	-$456.4M-36.2%	-$335.1M

AVTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$51.5M-4.9%	-$49.1M-59.9%	-$30.7M-14.7%	-$26.8M+62.3%	-$70.9M-74.9%	-$40.5M
Capital Expenditures	$7.5M	N/A	N/A	$95K-15.9%	$113K+79.4%	$63K
Free Cash Flow	-$59.0M	N/A	N/A	-$26.8M+62.2%	-$71.0M-74.9%	-$40.6M
Investing Cash Flow	-$81.7M-23055.1%	$356K+367.7%	-$133K-40.0%	-$95K+15.9%	-$113K-101.0%	$11.1M
Financing Cash Flow	$14.6M-91.7%	$175.8M+602.2%	$25.0M+270.4%	-$14.7M-113.8%	$106.8M+138.4%	$44.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$16.4M-43.7%	-$11.4M-20.4%	-$9.5M+37.1%	-$15.0M-30.5%	-$11.5M+29.2%	-$16.3M-162.5%	-$6.2M-124.2%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$13.3M+81.3%	-$70.9M	$0	$0	$0	$0-100.0%	$356K	$0
Financing Cash Flow	$14.4M+3163.8%	-$469K	$0-100.0%	$67.7M	$0+100.0%	-$472K-100.4%	$108.6M+10861100.0%	$1K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AVTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	33.3%-47.7pp	81.0%+8.6pp	72.4%-23.1pp	95.5%
Operating Margin	N/A	-15535.6%-14114.0pp	-1421.6%-1214.2pp	-207.4%+1314.2pp	-1521.6%-434.2pp	-1087.4%
Net Margin	N/A	-7965.8%-6326.3pp	-1639.5%-1408.7pp	-230.8%+1332.3pp	-1563.1%-615.2pp	-947.9%
Return on Equity	-94.2%-67.8pp	-26.4%+405.5pp	-431.9%	N/A	-365.6%-107.0pp	-258.5%
Return on Assets	-67.2%-43.9pp	-23.3%+126.9pp	-150.3%-25.4pp	-124.8%-19.7pp	-105.2%+39.9pp	-145.1%
Current Ratio	8.14-11.8	19.96+18.1	1.82+1.1	0.74-2.4	3.11+1.4	1.71
Debt-to-Equity	0.40+0.3	0.13-1.7	1.87+5.9	-4.06-6.5	2.48+1.7	0.78
FCF Margin	N/A	N/A	N/A	-148.7%+1166.7pp	-1315.4%-709.3pp	-606.1%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	138.9%
Operating Margin	N/A	N/A	N/A	N/A	-5165.1%	N/A	N/A	-1343.7%
Net Margin	N/A	N/A	N/A	N/A	9251.8%	N/A	N/A	-1433.0%
Return on Equity	-33.5%-13.6pp	-19.9%-9.1pp	-10.7%	N/A	109.3%	N/A	N/A	-111.8%
Return on Assets	-24.5%-8.1pp	-16.4%-6.9pp	-9.5%	N/A	23.4%-67.5pp	90.9%+188.9pp	-98.0%-59.1pp	-38.9%
Current Ratio	14.28+1.8	12.44-10.2	22.61+2.7	19.96+18.5	1.42+0.4	0.99+0.5	0.52-1.3	1.82
Debt-to-Equity	0.37+0.2	0.21+0.1	0.130.0	0.13-3.5	3.59+11.7	-8.12-6.1	-2.00-3.9	1.87
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Zura Bio Limited ZURA

$538.9M

Greenwich Lifesciences Inc GLSI

$297.7M

Agenus AGEN

$124.4M

Cybin Inc CYBN

$413.1M

Actuate Therapeutics Inc ACTU

$54.3M

Frequently Asked Questions

What is Avalo Therapeutics Inc's annual revenue?

Avalo Therapeutics Inc (AVTX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Avalo Therapeutics Inc's revenue growing?

Avalo Therapeutics Inc (AVTX) revenue declined by 100% year-over-year, from $441K to $0 in fiscal year 2025.

Is Avalo Therapeutics Inc profitable?

No, Avalo Therapeutics Inc (AVTX) reported a net income of -$78.3M in fiscal year 2025.

What is Avalo Therapeutics Inc's EBITDA?

Avalo Therapeutics Inc (AVTX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Avalo Therapeutics Inc's return on equity (ROE)?

Avalo Therapeutics Inc (AVTX) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Avalo Therapeutics Inc's free cash flow?

Avalo Therapeutics Inc (AVTX) generated -$59.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Avalo Therapeutics Inc's operating cash flow?

Avalo Therapeutics Inc (AVTX) generated -$51.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Avalo Therapeutics Inc's total assets?

Avalo Therapeutics Inc (AVTX) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Avalo Therapeutics Inc's capital expenditures?

Avalo Therapeutics Inc (AVTX) invested $7.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Avalo Therapeutics Inc spend on research and development?

Avalo Therapeutics Inc (AVTX) invested $50.1M in research and development during fiscal year 2025.

How many shares does Avalo Therapeutics Inc have outstanding?

Avalo Therapeutics Inc (AVTX) had 23M shares outstanding as of fiscal year 2025.

What is Avalo Therapeutics Inc's current ratio?

Avalo Therapeutics Inc (AVTX) had a current ratio of 8.14 as of fiscal year 2025, which is generally considered healthy.

What is Avalo Therapeutics Inc's debt-to-equity ratio?

Avalo Therapeutics Inc (AVTX) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avalo Therapeutics Inc's return on assets (ROA)?

Avalo Therapeutics Inc (AVTX) had a return on assets of -67.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avalo Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Avalo Therapeutics Inc (AVTX) had $15.9M in cash against an annual operating cash burn of $51.5M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Avalo Therapeutics Inc's Piotroski F-Score?

Avalo Therapeutics Inc (AVTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avalo Therapeutics Inc's earnings high quality?

Avalo Therapeutics Inc (AVTX) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Avalo Therapeutics Inc?

Avalo Therapeutics Inc (AVTX) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.